NanoViricides, Inc. (NYSE American: NNVC) has announced continued progress in advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial. The trial will evaluate an oral gummies formulation as a treatment for the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (DRC). The company reported that its proposed clinical trial has received approval from the DRC Pillar Committee, with preparations now underway for ethics and regulatory submissions.
NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical trials, offering potential advantages in resource-limited outbreak settings where infusion-based therapies are difficult to deploy. The DRC has reported 1,561 confirmed cases and 506 deaths as of July 6, according to the company, which also emphasized that no approved treatment or vaccine currently exists for the Bundibugyo strain. NanoViricides believes NV-387's broad-spectrum antiviral mechanism could provide activity against multiple ebolavirus strains.
The same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product shipped to the country for that study. This dual-track development highlights the versatility of NV-387. For more details, the full press release is available at https://ibn.fm/LaNwF.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate NV-387 is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company also has a drug candidate for Shingles, NV-HHV-1. However, the company cautions that the path to drug development is lengthy and requires substantial capital, with no assurance of successful clinical trials or final products.
The company's platform technology is based on the TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. NanoViricides holds a worldwide exclusive perpetual license for several drugs targeting specific human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex, Varicella-Zoster, Influenza, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses. The company intends to obtain licenses for RSV, Poxviruses, and Enteroviruses if initial research is successful.
For more information about NanoViricides, visit https://ibn.fm/NNVC. This news matters because it highlights a potential breakthrough in treating a deadly viral outbreak in a region with limited healthcare infrastructure, addressing an unmet medical need for a strain with no approved therapies.
